Clinical Trials Browser

Recruiting × NIH × olaparib × Clear all

NCT04858334 2026-04-22

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Phase 2 Recruiting

Gastrointestinal

Pancreatic Acinar Cell Carcinoma

NCT05554328 2026-04-22

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05564377 2026-04-21

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT04585958 2026-04-13

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Phase 1 Recruiting

Neoplasm Metastasis

NCT04633239 2026-04-13

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Phase 1 Recruiting

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT05411094 2026-04-13

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04086485 2026-04-07

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Phase 1/2 Recruiting

Carcinoid Tumor, Neuroendocrine Tumors